Pulse of ACC | NCDR.18, LBCTs for ACC.18 Announced, and More
ACC CEO to Head New Biopharmaceutical Company
ACC’s Chief Executive Officer, Shalom “Shal” Jacobovitz will be leaving the College effective Feb. 2, to lead CiVi Biopharma, Inc., a privately held biopharmaceutical company. Cathy Gates, ACC chief operating officer and executive vice president, will serve as interim CEO.
“There is no doubt that Shal is leaving a legacy that will continue to benefit the College well into the future,” says Mary Norine Walsh, MD, FACC, ACC president and chair of the Board of Trustees. “While he will be missed, his leadership over the last several years has ensured the ACC’s overall financial health, operational effectiveness and strategic direction are aligned to meet the needs of our members around the globe.” Read More >>>
Jacobovitz was hired in 2013 to leverage the organizational strengths of the College and to take advantage of opportunities associated with the changing health care environment. Since then, he has helped transform the College into a more nimble, strategic, innovative and accountable organization committed to transforming cardiovascular care and improving heart health. Specifically, he has built a culture of staff empowerment and played a key role in working with ACC leaders to transform the College’s governance structure and processes; foster a culture of innovation and continuous learning; and ensure alignment of programs and resources with the College’s strategic plan. Under his leadership the ACC has been recognized among the best places to work by Modern Healthcare.
"There is no doubt that Shal is leaving a legacy that will continue to benefit the College well into the future.While he will be missed, his leadership over the last several years has ensured the ACC’s overall financial health, operational effectiveness and strategic direction are aligned to meet the needs of our members around the globe. — Norine Walsh, MD, FACC
“It has been a privilege to lead the ACC over the last nearly five years,” Jacobovitz says. “I’m proud of what the College has accomplished during this time and I have no doubt that the Board of Trustees, working with Cathy and the rest of the College’s dedicated staff, will continue to work toward actualizing the vision of a world where innovation and knowledge optimize cardiovascular care and outcomes.”
The ACC will undertake a nationwide search for its next CEO. In the meantime, the BOT has appointed Gates as interim CEO.
ACC.18 Late-Breaking Cinical Trials Just Announced
Results from the ODYSSEY and VEST trials will kick of the Late-Breaking Clinical Trial (LBCT) sessions at ACC.18 in Orlando. The practice-changing lineup of LBCTs was announced on Jan. 19.
ACC.18 will feature five LBCT sessions in total, with a session on Monday, March 12 focused entirely on Interventional Cardiology. Among the interventional studies being presented:
- STOP-PAD: A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization to Enhance Wound Healing
- Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients with High-Risk Patent Foramen Ovale
- SMART-DATE: Safety of 6-Month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
- ANNEXA-4: Interim Report on the ANNEXA-4 Study: Andexanet For Reversal of Anticoagulation in Factor Xa - Associated Acute Major Bleeding
Learn more at accscientificsession.acc.org.
NCDR.18 to Focus on Trailblazing the Future
The 2018 NCDR Annual Conference (NCDR.18) will kick off March 7 at the Caribe Royale Orlando in Orlando, FL, with a focus on ways NCDR can and is going beyond data collection and helping hospitals and health systems blaze trails in quality improvement.
The three-day meeting will provide attendees with the opportunity to gain new NCDR registry-specific and industry knowledge, take away best practices through networking and posters, and discover tools and techniques to apply to quality improvement efforts. New this year, participants involved with more than one registry can customize their experience. In addition, ACTION Registry, ICD Registry, CathPCI Registry and STS/ACC TVT Registry agendas are divided into two, 40-minute sessions to allow more time for case scenarios.
Not to miss sessions, include the opening keynote session featuring Douglas. B. Fridsma, MD, PhD, president and CEO of the American Medical Informatics Association, as the Ralph G. Brindis Keynote Lecturer. Fridsma will tackle the barriers and opportunities for streamlining data capture and provide an outline for future data interoperability. The annual awards ceremony will recognize this year’s poster winners and new this year the meeting will close with a fun, new session called “It’s NCDR Jeopardy!” Selected contestants will answer questions in several categories ranging from NCDR history to quality improvement, in a similar format to the famed game show.
Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Congenital Heart Disease and Pediatric Cardiology, Dyslipidemia, Invasive Cardiovascular Angiography and Intervention, Prevention, Anticoagulation Management and ACS, Congenital Heart Disease, CHD and Pediatrics and Arrhythmias, CHD and Pediatrics and Interventions, CHD and Pediatrics and Quality Improvement, Lipid Metabolism, Novel Agents, Interventions and ACS, Interventions and Structural Heart Disease
Keywords: ACC Publications, Cardiology Interventions, Foramen Ovale, Patent, Factor Xa, Trustees, Secondary Prevention, Acute Coronary Syndrome, Quality Improvement, Leadership, Double-Blind Method, Registries, Data Collection, Percutaneous Coronary Intervention, American Medical Association, Stroke, Awards and Prizes, Wound Healing, Plasmids, Medical Informatics
< Back to Listings